Press Releases

« Back to all press releases

Innovators in Medical Research head to San Francisco for Milken Institute Partnering for Cures; Program focuses on patient-centered solutions and the impact of technology on biomedical research

Partnering for Cures
, the Milken Institute’s go-to meeting for accelerating patient-centered solutions and building powerful collaborations to fight disease, will be held on Tuesday, November 14. The meeting, organized by the Milken Institute center FasterCures, will be held in San Francisco for the first time as participants focus on the intersection of technology, innovation and philanthropy in biomedical research. Speakers include a diverse spectrum of leaders, including patients, policymakers, academics, advocates, philanthropists, regulators, investors and industry executives.

Who (partial list):
Atul Butte, Director, Institute for Computational Health Sciences, University of California, San Francisco
Eric Dishman, Director, Precision Medicine Initiative Cohort Program, National Institutes of Health
Kathy Giusti, Founder, Multiple Myeloma Research Foundation
Kathy Hudson, CEO, People-Centered Research Foundation
Regis Kelly, Director, QB3
Todd Sherer, CEO, The Michael J. Fox Foundation for Parkinson's Research
Tania Simoncelli, Director of Policy for Science, Chan Zuckerberg Initiative
Roni Zeiger, Co-founder and CEO, Smart Patients; Former Chief Health Strategist, Google
Alice Zhang, CEO and Co-founder, Verge Genomics
Michael Milken, Chair, Milken Institute

Tuesday, November 14, 2017, 8:00 a.m. – 5:00 p.m.

Intercontinental San Francisco
888 Howard Street
San Francisco, Calif. 94103

Program Schedule:

9:00 AM – 9:15 AM: Welcome. Kimberly McCleary, Acting Executive Director, Managing Director, FasterCures

9:15 AM – 9:30 AM: Time=Lives Talk: When the Personal and Professional Collide
When biomedical researchers like Reg Kelly confront a major disease such as dementia in their personal lives, they quickly recognize that effective cures for their loved ones require collaboration across conventional fields such as immunology, neurology, and stem cell biology.
Speaker: Regis Kelly, Director, QB3; Byers Family Distinguished Professor, University of California, San Francisco

9:30 AM – 10:30 AM: PLENARY: "Recommended for You:" Can Direct-to-Consumer Expertise Inform Precision Medicine? Most of us appreciate the way the predictive analytics employed by companies like Amazon and Netflix seem to anticipate our needs and match us with the right solutions. Where are we in the quest to use that power in the service of developing personalized models for treating and curing disease?
Margaret Anderson, Managing Director, Deloitte Consulting
Silas Buchanan, Co-Founder and CEO, Institute for eHealth Equity
Eric Dishman, Director, Precision Medicine Initiative Cohort Program, National Institutes of Health
Kathy Giusti, Founder, Multiple Myeloma Research Foundation; Co-Chair, HBS Kraft Precision Medicine Accelerator
Christine Lemke, Co-Founder and President, Evidation Health

11:00 AM – 12:00 PM: Medicine Needs Data Scientists. Massive volumes of data are generated as part of biomedical research and everyday clinical care. While data have always driven biomedical innovation, the development of the internet and big data tools provide new opportunities to collaborate, analyze, and accelerate progress.
Cynthia Grossman, Associate Director, Science of Patient Input, FasterCures
Nate Crisel, Vice President and Head, Real World Informatics and Analytics, Astellas
Martin Entwistle, President and CEO, Ares Health Systems
Magali Haas, CEO and President, Cohen Veterans Bioscience
Guneet Walia, Senior Director, Research and Medical Affairs, Bonnie J. Addario Lung Cancer Foundation

Putting Patients at the Center of the Value Conversation.

Value in health care can mean different things to different stakeholders. Payer priorities may not match up with those of manufacturers, and both may assess value entirely differently than public health entities. However, no matter which of these stakeholders is measuring value, it’s important that value assessments always robustly consider...
Sara Radcliffe, President and Chief Executive Officer, California Life Sciences Association
Andy Baskin, National Medical Director, Quality and Provider Performance Measurement, Aetna
Nancy McGee, Executive Vice President, Avalere Health
Amy O'Sullivan, Senior Director and Head, Health Economics and Outcomes Research, Alkermes
Michael Siegel, Vice President, Research Programs, National Psoriasis Foundation

12:45 PM – 1:45 PM
Artificial Intelligence and Machine Learning in Medical R&D: Hope or Hype? Applications of artificial intelligence and machine learning to health care and research have been exploding over the last year – and sometimes blowing up as we climb the learning curve. There is great hope, however, that these technologies will reduce drug discovery times and be the ultimate enabler of precision medicine.
Atul Butte, Director, Institute for Computational Health Sciences, and Priscilla Chan and Mark Zuckerberg Distinguished Professor, University of California, San Francisco
John Baldoni, Senior Vice President, DPU Head, ln Silico Discovery, GSK Pharmaceuticals
Iya Khalil, Co-Founder and Chief Commercial Officer, GNS Healthcare
Alice Zhang, CEO and Co-founder, Verge Genomics

2:15 PM – 3:15 PM
Health Citizenship: Creating a New Social Compact for Health Our health is both an individual and a collective responsibility as we all bear the costs of disease and reap the benefits of healthier communities. Technology has provided new tools to enable people to easily access their health data and understand their health status, and the federal government has declared that we have a right to our electronic health records. How can individuals be empowered to control their health data and use it to improve their own health? What new opportunities do we have to support research and improve prevention and treatment? How can we create not just a culture of health but of health citizenship?
Claudia Williams, CEO, Manifest MedEx
Kathy Hudson, CEO, People-Centered Research Foundation
Beth Meagher, Principal, Deloitte Consulting LLP
Jennifer Mills, Director, Patient Engagement and Novel Patient-Focused Partnerships, Genentech
Lucia Savage, Chief Privacy and Regulatory Officer, Omada Health
Roni Zeiger, Co-Founder and CEO, Smart Patients; Former Chief Health Strategist, Google

Tech Culture Meets Medical Research Culture Many of the behaviors slowing progress in the discovery and development of new medical products are challenges that organizations everywhere have been confronting for decades, if not centuries: lack of effective communication and collaboration, silo-ization of information and expertise, incentives not aligned with the collective behaviors we want to see.
Luke Timmerman, Founder and Editor, Timmerman Report
Jeff Conklin, Senior Vice President, Business Insights and Analytics, Bristol-Myers Squibb
Riley Ennis, Co-Founder and Chief Operating Officer, Freenome
Eri Gentry, Co-founder, BioCurious; Science and Technology Researcher, Institute for the Future
Lisa Suennen, Senior Managing Director, Healthcare Investing, GE Ventures; Managing Partner, Venture Valkyrie, LLC
Matt Wilsey, Chairman, President, and Co-founder, Grace Science Foundation

3:30 PM – 4:00 PM: P4C Unplugged. A conversation led by Michael Milken, Chairman, Milken Institute

4:00 PM – 5:00 PM: A New Generation of Philanthropy Joins the Battle Against Disease. Following in Bill Gates’ footsteps is a new generation of entrepreneurs who are pledging significant portions of their philanthropy to solving humankind’s most pressing health challenges. Along with their funding, they are bringing new models of philanthropy as well as expectations that the medical research ecosystem is having to adapt to. Are next-gen philanthropists changing the rules of the game? How are venture philanthropy organizations leveraging the financial and other assets of these activist philanthropists to accelerate their missions?
Richard Ditizio, President and Chief Operating Officer, Milken Institute
David Beier, Managing Director, Bay City Capital
David Panzirer, Trustee, The Leona M. and Harry B. Helmsley Charitable Trust
Todd Sherer, CEO, The Michael J. Fox Foundation for Parkinson's Research
Tania Simoncelli, Director of Policy for Science, Chan Zuckerberg Initiative
Mark Smolinski, Chief Medical Officer and Director, Global Health Threats, Skoll Global Threats Fund


About FasterCures
FasterCures, a Washington, D.C.-based center of the Milken Institute, is driven by a singular goal: to save lives by speeding up and improving the medical research system. It focuses on cutting through the roadblocks that slow medical progress by spurring cross-sector collaboration, cultivating a culture of innovation and engaging patients as partners. FasterCures works across sectors and diseases to accelerate the process by which great advances in science and technology turn into meaningful medical solutions for patients. For more information, visit  

About the Milken Institute
The Milken Institute is a nonprofit, nonpartisan think tank determined to increase global prosperity by advancing collaborative solutions that widen access to capital, create jobs and improve health. We do this through independent, data-driven research, action-oriented meetings and meaningful policy initiatives. For more information, visit

Geoffrey Baum
Director, Media Relations
(310) 570-4689;